Faculty Opinions recommendation of Metformin represses drug-induced expression of CYP2B6 by modulating the constitutive androstane receptor signaling.

Author(s):  
Santosh Kumar
2013 ◽  
Vol 85 (2) ◽  
pp. 249-260 ◽  
Author(s):  
Hui Yang ◽  
Brandy Garzel ◽  
Scott Heyward ◽  
Timothy Moeller ◽  
Paul Shapiro ◽  
...  

2014 ◽  
Vol 11 (3) ◽  
pp. 60-61
Author(s):  
Sveta Igorevna Andreeva

Currently, metformin is a major hypoglycemic agents for the treatment of type 2 diabetes. The main antihyperglycemic effect of metformin - suppression of hepatic gluconeogenesis and glycolysis. However, type 2 diabetes are usually associated with other diseases and associated comorbid conditions that require polifarmakologic treatment.


Redox Biology ◽  
2020 ◽  
Vol 30 ◽  
pp. 101403 ◽  
Author(s):  
Jayshree L. Hirpara ◽  
Kothandharaman Subramaniam ◽  
Gregory Bellot ◽  
Jianhua Qu ◽  
Serena Seah ◽  
...  

2019 ◽  
Vol 20 (19) ◽  
pp. 4855 ◽  
Author(s):  
Yasunari Matsuzaka ◽  
Yoshihiro Uesawa

The constitutive androstane receptor (CAR) plays pivotal roles in drug-induced liver injury through the transcriptional regulation of drug-metabolizing enzymes and transporters. Thus, identifying regulatory factors for CAR activation is important for understanding its mechanisms. Numerous studies conducted previously on CAR activation and its toxicity focused on in vivo or in vitro analyses, which are expensive, time consuming, and require many animals. We developed a computational model that predicts agonists for the CAR using the Toxicology in the 21st Century 10k library. Additionally, we evaluate the prediction performance of novel deep learning (DL)-based quantitative structure-activity relationship analysis called the DeepSnap-DL approach, which is a procedure of generating an omnidirectional snapshot portraying three-dimensional (3D) structures of chemical compounds. The CAR prediction model, which applies a 3D structure generator tool, called CORINA-generated and -optimized chemical structures, in the DeepSnap-DL demonstrated better performance than the existing methods using molecular descriptors. These results indicate that high performance in the prediction model using the DeepSnap-DL approach may be important to prepare suitable 3D chemical structures as input data and to enable the identification of modulators of the CAR.


2019 ◽  
Vol 171 (1) ◽  
pp. 132-145
Author(s):  
Andrew J Lickteig ◽  
Youcai Zhang ◽  
Curtis D Klaassen ◽  
Iván L Csanaky

AbstractAccumulation of bile acids (BAs) in hepatocytes has a role in liver disease and also in drug-induced liver injury. The constitutive androstane receptor (CAR) has been shown to protect against BA-induced liver injury. The polymorphism of CAR has recently been shown to modify the pharmacokinetics and pharmacodynamics of various drugs. Thus, it was hypothesized that polymorphism of CAR may also influence BA homeostasis. Using CAR-null and WT mice, this study modeled the potential consequences of CAR polymorphism on BA homeostasis. Our previous study showed that chemical activation of CAR decreases the total BA concentrations in livers of mice. Surprisingly the absence of CAR also decreased the BA concentrations in livers of mice, but to a lesser extent than in CAR-activated mice. Neither CAR activation nor elimination of CAR altered the biliary excretion of total BAs, but CAR activation increased the proportion of 6-OH BAs (TMCA), whereas the lack of CAR increased the excretion of taurocholic acid, TCDCA, and TDCA. Serum BA concentrations did not parallel the decrease in BA concentrations in the liver in either the mice after CAR activation or mice lacking CAR. Gene expression of BA synthesis, transporter and regulator genes were mainly similar in livers of CAR-null and WT mice. In summary, CAR activation decreases primarily the 12-OH BA concentrations in liver, whereas lack of CAR decreases the concentrations of 6-OH BAs in liver. In bile, CAR activation increases the biliary excretion of 6-OH BAs, whereas absence of CAR increases the biliary excretion of 12-OH BAs and TCDCA.


1995 ◽  
Vol 67 ◽  
pp. 28
Author(s):  
Yoshiaki Fujii-Kurivama ◽  
Masatsugu Ema ◽  
Akira Kobayashi ◽  
Junsei Mimura ◽  
Kazuhiro Sogawa

2021 ◽  
Vol 181 (1) ◽  
pp. 58-67
Author(s):  
Amina I Shehu ◽  
Junjie Zhu ◽  
Jianhua Li ◽  
Jie Lu ◽  
Deborah McMahon ◽  
...  

Abstract Liver-related diseases including drug-induced liver injury are becoming increasingly prominent in AIDS patients. Cobicistat (COBI) is the backbone of multiple regimens for antiretroviral therapy. The current work investigated the mechanisms of adverse drug-drug interactions associated with COBI that lead to liver damage. For individuals co-infected with HIV and tuberculosis (TB), the World Health Organization recommends the initiation of TB treatment followed by antiretroviral therapy. Rifampicin (RIF), a first line anti-TB drug, is a human specific activator of pregnane X receptor (PXR). Using PXR-humanized mice, we found that RIF-mediated PXR activation potentiates COBI hepatotoxicity. In contrast, rifabutin, a PXR-neutral analog of RIF, has no impact on COBI hepatotoxicity. Because of the crosstalk between PXR and the constitutive androstane receptor (CAR), the role of CAR in COBI hepatotoxicity was also investigated. Similar to PXR, ligand-dependent activation of CAR also potentiates COBI hepatotoxicity. Our further studies illustrated that PXR and CAR modulate COBI hepatotoxicity through the CYP3A4-dependent pathways. In summary, the current work determined PXR and CAR as key modulators of COBI hepatotoxicity. Given the fact that many prescription drugs and herbal supplements can activate PXR and CAR, these two receptors should be considered as targets to prevent COBI hepatotoxicity in the clinic.


Sign in / Sign up

Export Citation Format

Share Document